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Purpose/Objective: In line with the implementation of new treatment 
methods like IMRT and RapidArc, where the margins are reduced and 
the treatment plans demand high accuracy in the daily treatment we 
felt obliged to have a closer look at our strategy for verification of the 
treatment field. Even though we already have used IGRT for prostate 
cancer patients since 2005, which was extended in 2009 to include 
patients with brain tumours, we decided to extend our IGRT strategy 
further to all patient groups. In our clinic we have 11 accelerators and 
treat about 260 patients daily. 
Materials and Methods: In the autumn of 2010, we had our first 
meeting in an interdisciplinary group consisting of physicists, 
physicians and RTTs (nurses). The purpose of the group was to make 
an IGRT strategy for all patient groups. One of our challenges was our 
accelerators, which were of different models, resulting in 4 different 
verification systems - portal image, on board image (OBI), cone beam 
CT and Exactrac. The task of the group was to define which 
verification systems was best for which diagnosis, define margins for 
set-up uncertainties, whether to use bone or soft-tissue match, make 
plans for a physician/physicist control of the match and to educate 
the staff. 
Results: In 2012, approximately 95 % of the treatments are image 
guided which is equivalent to 55.000 image guided treatments per 
year. To make the transition as smooth as possible, it was necessary 
to make a gradual transition. We started out testing the new strategy 
on 3 accelerators for 4 months, and all physicists, physicians and RTTs 
had a 2 hour theoretical lesson in the changes in their part of the 
treatment preparation and therapy. After that, the staff had hands-on 
lessons for a couple of hours. During the first 4 months, the 
interdisciplinary group met to make small adjustments. As of 
September 1. 2011 IGRT is a daily routine in our clinic.  
Conclusions: The transition has not been as difficult as we could have 
feared. All members of the staff have worked together to make it 
happen. The RTTs say that it makes them feel more comfortable to 
give a high precision treatment now that they check every day that 
the positioning of the patient is correct. Reports of unintended events 
linked to IGRT has drop from 10 to fewer than 3 a year. The process of 
adjusting the IGRT strategy to changes in the clinic, new treatment 
methods and strategies is on-going.  
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Purpose/Objective: The purpose of this study was to systematically 
analyse and evaluate the effectiveness of interstitial brachytherapy on 
periocular squamous cell carcinoma (POSCC) in horses in decreasing 
tumour recurrence rates. A further evaluation of treatment technique 
will define appropriateness of wire placement in relation to dose 
distribution parameters. 
Materials and Methods: The study included records of 104 horses with 
histologically or clinically confirmed periocular squamous cell 
carcinoma (POSCC). The patients were treated in a rural Australian 
clinic between 1999 and 2007 with permanent Gold (Au198) wire 
manually implanted without the use of radiation therapy specific 
planning software, dosimetry or expertise. Recurrence was defined as 
the post-irradiation regrowth of SCC at the same site of treatment. 
Follow-up information was obtained for 44 of the 104 cases. 
Treatment applications for each individual case (104) were modelled 
and replicated and dose distributions calculated through the use of 
Varian BrachyVisionTM Treatment Planning Software.  
Results: Recurrence was noted in 30 of the 44 cases where follow-up 
was evident (as reported via owner or veterinarian). The treated 
lesions were reported to have resolved in 14 of the 44 cases, however, 
follow-up information was not available for 60/104 cases.  
Conclusions: The results of this study question the efficacy of 
brachytherapy treatment applications without appropriate radiation 
therapy planning, dosimetry and expertise. The results further support 
the need for protocol based treatment implementation within 
veterinary oncology to mirror current applications in human 
treatments and with a view to enhancing treatment outcomes with 
reference to recurrence rates. 
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Purpose/Objective: To report the tolerability of breast IORT using a 
single channel balloon catheter applicator.  
Materials and Methods: From February 2011 to November 2012, we 
treated 60 patients aged 36 to 85 (median 63) years by intraoperative 
HDR-afterloading therapy intended as a tumour bed boost. According 
to ASTRO suitability criteria, 19 of them would have qualified for 
partial breast irradiation (PBI)only, 24 would have been considered 
cautionary. Patients were eligible for the method with cT1 (n=49) or 
small cT2 (n=11) tumours, no multicentricity, and a skin-tumour-
distance of > 1.5 cm. Irradiation was performed using balloon catheter 
applicators with volumes of 35(n=50), 40(n=9) or 50 ml (n=1), resulting 
in 1 cm depth tissue doses of 8.9, 9.1 and 9.5 Gy, respectively. The 
intended dose of 20 Gy to the applicator surface was given in 51 
patients. In 9 patients, irradiation was terminated early due to an 
excess in online-measured skin dose (limit set at 8 Gy). Breast 
volumes ranged from 317 to 3893 (median:1037) ml. According to 
ASTRO quality criteria for PBI, not more than 60% of breast volume 
should receive more than 50% of the prescribed dose in 1 cm tissue 
depth. This was fulfilled in all but two patients with breast volumes of 
317 and 423 ml. Percutaneous whole breast irradiation (WBI) (50.4 Gy, 
3D-conformal) in patients not receiving postoperative chemotherapy 
(n=38) was started 33 to 63 (median 42) days after IORT. In 22 cases, 
final histology revealed indications for chemotherapy. Whole breast 
irradiation(WBI) was performed thereafter, starting 138 to 238 
(median: 171) days after IORT. 
Results: Prolongation of anaesthesia due to irradiation time and 
transport was 40 minutes in mean. Measured skin dose ranged from 
1.381 to 8.2 (median: 5.6) Gy. Acute side effect was a mild or 
moderate erythema in20% of patients decreasing till the start of WBI 
and then aggravating again. Edema was seen in 40% of patients some 
days after IORT, resolving till start of WBI, appearing again as a side 
effect of EBRT and decreasing again in the year after RT. Induration of 
the tumour bed started some days after IORT, resolved inpatients 
receiving postoperative chemotherapy before WBI, but was seen as a 
side effect of EBRT, slowly resolving during follow-up. Skin 
desquamation was seen only as a side effect of WBI. Patients receiving 
chemotherapy showed rather less side effects of WBI due to the 
prolonged time between IORT and EBRT. 
Conclusions: The side effects observed after intraoperative HDR-
balloon catheter afterloading plus WBI did not differ neither in quality 
nor strength from what we see in WBI plus percutaneous tumour bed 
boost. Thus, we consider the method to be a safe alternative to 
percutaneous boost and prefer it for boosting small breast cancers, as 
with the IORT application we are certain to reduce geographic miss of 
the tumour bed. 
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Purpose/Objective: Rectal volume change is a proved source of 
variation during external beam radiotherapy. Vaginal cuff 
brachytherapy is one of the most widely and settle brachytherapy 
procedures wordwile. Some groups advocate a previous rectum 
cleansing, despite this fact no studies exist analysing the 
consequences of rectal distention during vaginal cuff brachytherapy. 
The aim of our study was to define how rectal distention affects 
dosimetric values on organs at risk. 
Materials and Methods: CT sets (337) derived from 92 patients 
treated with vaginal cuff brachytherapy were re-segmented and re-
planned for study purpose under the same parameters. Rectum DVH 
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values were extracted and multiple regression was carried out. 
Variables analysed were: cylinder angle placement related to the 
craneo-caudal patient axis, rectum volume, cylinder diameter, type of 
rectal content. 
Results: Rectum volume had a significant association (p<.0001) with 
the type of rectal content. Multiple linear regression model found 
cylinder angle position, rectal volume, type of rectal content and 
cylinder diameter as the significant variables related to high rectum 
DVH dose values analysed (table). Cylinders pointing toward rectum, 
large rectum volumes, air and contrast taking part of the rectal 
content and the use of small cylinders were related to high dose 
values. 
 
 Conclusions: Despite vaginal cuff brachytherapy is a well settled 
procedure, a little way of improvement could be achieved taking care 
of the thecnique procedure; from our results, cleaning the rectum 
prior to the procedure could be one among them. 
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Purpose/Objective: This study aimed to determine the current 
application of image-guided brachytherapy (IGBT) for patients with 
uterine cervical cancer in Japan. 
Materials and Methods: In July 2012, questionnaires were sent to 171 
Japanese centers identified as having a high-dose rate (HDR) 
brachytherapy machine. The questionnaire consisted of 28 items 
regarding current practice patterns and future plans for IGBT for 
patients with cervical cancer. 
Results: Responses were received from 144 (84%) centers. Only 2% of 
the centers used ultrasound guidance routinely for applicator 
insertion, and 24% used it occasionally. Images obtained after 
applicator insertion were orthogonal X-rays (XP) alone in 59%, XP and 
CT in 28%, XP and CT and MRI in 1%, and CT/MRI without XP in 6%. MRI 
was obtained in only 2% of the centers. 3D planning for actual 
treatment was performed in 15% of the centers, while 35% performed 
CT/MRI with the applicators in place. Reasons the remaining 20% of 
the centers did not perform 3D planning for actual treatment (use 2D 
planning data with XP alone) were: limited physician time (72%), 
limited number of staff members (48%), insufficient planning software 
(31%), unproven benefit (3%) and insufficient knowledge/training in 3D 
planning (24%). CT/MRI-compatible applicators were utilized in 22% of 
the centers where the CT/MRI were acquired. The technical details of 
IGBT were analyzed for 22 centers performing the 3D planning for 
actual treatment. Contouring of organs at risk was done for the 
rectum in the 73% of the centers, for the bladder in 68%, for the 
sigmoid colon in 45%, and for the small intestine in 41%. Regarding 
target volumes, GTV-BT was contoured in 23% of the centers, HR-CTV 
in 45%, and IR-CTV in 14%. Doses were prescribed to point A alone in 
55% of the centers, point A and HR-CTV in 41%, and HR-CTV alone in 
0%. Applicator reconstruction was performed by radiation 
technologists (RT) in 68% of the centers and radiation oncologists (RO) 
in 32%. Contouring was mainly done by the RO (95%). Dose calculation 
was done by the RO (86%) and the RT (72%). Medical physicist 
involvement in these processes was limited: 9% of the centers for 
applicator construction, 9% for contouring, and 14% for dose 
calculation. Fifty-five percent of the centers where 3D planning is 
currently withheld hope to implement it for actual treatment. 
Conclusions: Although over 1/3 of the centers obtained CT images 
after applicator insertion, the use of 3D treatment planning remains 
limited in Japan.  
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Purpose/Objective: In brachytherapy also image-guidance plays an 
important role. For GYN treatments it is standard to acquire CT 
images and preferably also MR images prior to each treatment to 
calculate the dose of the day. The dose of the complete treatment is 
calculated by adding the dose metrics of each fraction e.g. V100 for 
target and D0.1cc or D2cc for OAR. It makes the safe conservative but 
incorrect assumption that the same part of the OAR always receives 
the highest dose. The dose calculated this way often limits the 
prescription dose or the target coverage. We investigate an 
alternative method to assess the cumulative dose for a treatment 
course; the use of deformable image registration (DIR) software to 
track the deformations of the OAR due to the bladder and rectum 
filling as well as by the insertion of the applicator. 
Materials and Methods: CT images are acquired during each fraction. 
Rigid registration is preformed, followed by DIR. DIR can be either 
based only on the 3D images or partially on the 3D images and on the 
organ contours. One of the problems in the pelvic region is the lack of 
contrast between structures in CT images that makes it difficult for 
DIR based on images alone. We investigated two possible solutions: (1) 
the use of CT images combined with contours (2) the use of the CT 
image modified to artificially increase the contrast in certain 
volumes.We use two optical flow deformation algorithms in parallel: a 
morphon algorithm or a demon algorithm to match the images and a 
demons algorithm applied to distance maps computed from the 
contours. The dose matrix from day2 exported from a treatment 
planning is deformed using the calculated deformation field in our 
software. We also use in-house software to generate CT images for 
simulations studies. 
Results: The first results on dose accumulation (fig 1) are based on 
contrast-enhanced CT images or the original CT image with the 
bladder contours as constraint. The use of the contrast-enhanced 
images helps to guide the DIR more than the use of the contours as 
shown by the higher DICE indices. Even for good contour matching, a 
small local error in the deformation can have significant consequences 
for the dose distribution, resulting in our example in dose metrics 
exceeding the ones calculated using the GEC-ESTRO recommendation, 
which is unphysical. 
  
Conclusions: Using DIR based on image features and contours,we 
 
